Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Current Assets (2016 - 2025)

Historic Current Assets for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $2.7 million.

  • Alaunos Therapeutics' Current Assets fell 2436.62% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 2436.62%. This contributed to the annual value of $2.8 million for FY2024, which is 6665.05% down from last year.
  • According to the latest figures from Q3 2025, Alaunos Therapeutics' Current Assets is $2.7 million, which was down 2436.62% from $3.7 million recorded in Q2 2025.
  • Alaunos Therapeutics' Current Assets' 5-year high stood at $112.7 million during Q1 2021, with a 5-year trough of $1.1 million in Q1 2025.
  • Its 5-year average for Current Assets is $37.9 million, with a median of $18.8 million in 2023.
  • As far as peak fluctuations go, Alaunos Therapeutics' Current Assets crashed by 8464.47% in 2023, and later crashed by 2009.41% in 2025.
  • Alaunos Therapeutics' Current Assets (Quarter) stood at $78.8 million in 2021, then tumbled by 31.75% to $53.8 million in 2022, then tumbled by 84.64% to $8.3 million in 2023, then tumbled by 66.65% to $2.8 million in 2024, then fell by 2.54% to $2.7 million in 2025.
  • Its Current Assets stands at $2.7 million for Q3 2025, versus $3.7 million for Q2 2025 and $1.1 million for Q1 2025.